ZVRA

Zevra Therapeutics Inc

Oct 16 • 03:30PM ET

11.34

-0.44 -3.74 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD ALNY REGN BMRN IONS NBIX SRPT EXEL BLUE

| Held by: VTI IWM IWO VXF IBB XPH VTWO SURI IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.05	Insider Own	0.80%	Shs Outstand	56.14M	Perf Week	4.81%
Market Cap	636.57M	Forward P/E	20.67	EPS next Y	0.55	Insider Trans	-3.30%	Shs Float	55.69M	Perf Month	54.71%
Enterprise Value	496.24M	PEG	-	EPS next Q	-0.03	Inst Own	65.03%	Short Float	16.28%	Perf Quarter	-6.05%
Income	2.64M	P/S	10.26	EPS this Y	152.69%	Inst Trans	0.40%	Short Ratio	4.90	Perf Half Y	60.85%
Sales	62.02M	P/B	5.33	EPS next Y	-54.32%	ROA	1.32%	Short Interest	9.07M	Perf YTD	35.97%
Book/sh	2.13	P/C	3.14	EPS next 5Y	-	ROE	3.53%	52W High	13.16 -13.83%	Perf Year	40.35%
Cash/sh	3.61	P/FCF	-	EPS past 3/5Y	-2.57% 29.64%	ROIC	1.48%	52W Low	6.19 83.20%	Perf 3Y	94.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.24% 12.96%	Gross Margin	56.39%	Volatility	6.73% 7.14%	Perf 5Y	7.39%
Dividend TTM	-	EV/Sales	8.00	EPS Y/Y TTM	96.76%	Oper. Margin	-97.41%	ATR (14)	0.66	Perf 10Y	-96.30%
Dividend Ex-Date	-	Quick Ratio	7.81	Sales Y/Y TTM	158.57%	Profit Margin	4.26%	RSI (14)	64.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.85	EPS Q/Q	386.73%	SMA20	15.06%	Beta	1.48	Target Price	23.22
Payout	-	Debt/Eq	0.53	Sales Q/Q	481.73%	SMA50	20.30%	Rel Volume	0.87	Prev Close	11.78
Employees	59	LT Debt/Eq	0.53	Earnings	Aug 12 AMC	SMA200	28.54%	Avg Volume	1.85M	Price	11.34
IPO	Apr 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-46.55% 14.74%	Trades		Volume	1,490,706	Change	-3.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-25	Initiated	H.C. Wainwright	Buy	$26
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight	$25
Oct-07-24	Initiated	Guggenheim	Buy	$20
Sep-24-24	Reiterated	Maxim Group	Buy	$18 → $25
Sep-24-24	Initiated	JMP Securities	Mkt Outperform	$17
Apr-02-24	Reiterated	Maxim Group	Buy	$12 → $18
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy	$12

Today 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 05:51PM	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.23%
01:10PM	Zevra Therapeutics Stock Sees Healthy RS Rating Jump To 73 (Investor's Business Daily)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) +6.37%
Sep-18-25 07:30AM	Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA (arimoclomol) and OLPRUVA (sodium phenylbutyrate) (GlobeNewswire) +8.32%
02:27PM	Loading…
Sep-17-25 02:27PM	Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (Insider Monkey)
Sep-04-25 07:30AM	Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) (GlobeNewswire)
Aug-28-25 07:30AM	Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) (GlobeNewswire)
Aug-26-25 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-15-25 04:25PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised) (Zacks) +5.96%
Aug-13-25 04:09PM	Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' (Investor's Business Daily) -19.81% -5.62%
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
03:11AM	Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:50PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Zevra Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-11-25 09:27AM	Zevra Therapeutics Inc (ZVRA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:10AM	3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates (Zacks)
Aug-08-25 08:50AM	What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing' (Zacks)
Aug-06-25 07:30AM	Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-05-25 10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Aug-04-25 07:30AM	Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call (GlobeNewswire)
Jul-31-25 09:55AM	Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 06:00AM	Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Jul-18-25 07:30AM	Zevra Therapeutics Announces MIPLYFFA and OLPRUVA Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) (GlobeNewswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice (Zacks)
09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
07:30AM	Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism (GlobeNewswire)
Jul-15-25 09:55AM	Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know (Zacks)
08:50AM	Loading…
08:50AM	Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) (Zacks)
Jul-11-25 07:30AM	Zevra Therapeutics Announces MIPLYFFA (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference (GlobeNewswire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
May-29-25 04:35PM	Zevra Announces Final Results of 2025 Annual Meeting of Stockholders (GlobeNewswire)
May-27-25 01:03PM	Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT (Insider Monkey)
May-21-25 07:30AM	All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees (GlobeNewswire)
May-14-25 10:53AM	Q1 2025 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
May-13-25 05:20PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
May-12-25 09:33AM	Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 07:30AM	Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call (GlobeNewswire) -7.50%
May-01-25 04:05PM	Zevra Therapeutics to Participate in the Citizens Life Science Conference (GlobeNewswire)
Apr-21-25 07:22AM	Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders (GlobeNewswire)
Apr-17-25 07:30AM	Zevra Announces Publication of MIPLYFFA Mechanism of Action Manuscript in Molecular Genetics and Metabolism (GlobeNewswire)
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha) -6.52%
Apr-07-25 07:30AM	Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (GlobeNewswire)
Apr-03-25 06:38AM	Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (Seeking Alpha)
Mar-31-25 04:12PM	Zevra Therapeutics Files Preliminary Proxy (GlobeNewswire)
Mar-12-25 12:31PM	Q4 2024 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:06AM	Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Mar-11-25 06:15PM	Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:22PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports Full Year 2024 and Fourth Quarter Financial Results (GlobeNewswire)
Feb-28-25 07:30AM	Zevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
06:40AM	Praxis hits trial setback; Bristol Myers lays off staff in New Jersey (BioPharma Dive)
Feb-27-25 06:16PM	Zevra sells priority review voucher for $150m to support drug launches (Pharmaceutical Technology) +5.41%
07:30AM	Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million (GlobeNewswire)
Feb-26-25 09:46AM	Zevra to Report 2024 Fourth Quarter and Full Year Financial Results (GlobeNewswire)
Feb-24-25 04:02PM	Zevra to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:30AM	Zevra Therapeutics to Present at the 21st Annual WORLDSymposium (GlobeNewswire)
Jan-29-25 04:05PM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Dec-17-24 07:30AM	Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 (GlobeNewswire)
Dec-09-24 02:48AM	A drug for fewer than 1,000 patients? Awareness and diagnosis are key. (Pharma Voice)
Dec-06-24 05:00PM	Zevra Therapeutics Announces Organizational Changes (GlobeNewswire)
Nov-26-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-23-24 06:32AM	Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease (TipRanks)
Nov-21-24 04:51PM	Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Nov-13-24 02:17AM	Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-12-24 06:00PM	Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Zevra Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-11-24 04:36PM	Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting (GlobeNewswire)
07:15AM	Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-24 07:30AM	Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 (GlobeNewswire)
Oct-31-24 07:30AM	Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 (GlobeNewswire)
Oct-29-24 10:01AM	Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline (Zacks)
Oct-10-24 07:30AM	Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.49%
Oct-09-24 06:19PM	Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
09:00AM	NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders (GlobeNewswire)
Sep-25-24 06:22AM	Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? (Zacks) -8.77%
Sep-24-24 07:30AM	Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 (GlobeNewswire) +9.10%
Sep-23-24 04:12AM	FDA approves Zevra Therapeutics Miplyffa for Niemann-Pick disease (Pharmaceutical Technology) -5.96%
Sep-20-24 01:27PM	Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease (Benzinga)
12:08PM	Zevra Therapeutics' MIPLYFFA (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C (GlobeNewswire)
Sep-06-24 08:30AM	Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (GlobeNewswire)
Aug-29-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 05:30PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-09-24 12:00AM	Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) -10.55%
Aug-08-24 04:01PM	Zevra Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-07-24 09:34AM	Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference (GlobeNewswire) -8.12%
Aug-06-24 10:00AM	Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline (Zacks)
Aug-05-24 11:13AM	Zevra wins FDA panel backing for previously rejected arimoclomol (Pharmaceutical Technology) +25.08%
Aug-02-24 05:50PM	FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C (GlobeNewswire)
Jul-30-24 08:38AM	Zevra Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire) -5.82%
Jul-10-24 03:04PM	Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug (Zacks)

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McFarlane Neil F.	President and CEO	Oct 10 '25	Sale	10.82	19,500	210,908	222,016	Oct 10 07:17 PM
NEIL F MCFARLANE	Director	Oct 10 '25	Proposed Sale	10.82	19,500	210,990		Oct 10 04:17 PM
FAVORITO TAMARA A	Director	Sep 12 '25	Buy	7.79	3,175	24,718	3,894	Sep 16 04:15 PM
Shih Alvin	Director	Sep 12 '25	Buy	7.89	20,000	157,800	20,000	Sep 15 04:07 PM
Bode John B	Director	Aug 19 '25	Buy	9.16	5,000	45,825	45,000	Aug 20 04:38 PM
Thompson Rahsaan	Chief Legal & Compliance	Jun 26 '25	Sale	9.21	24,000	221,004	42,666	Jun 30 05:02 PM
RAHSAAN THOMPSON	Officer	Jun 26 '25	Proposed Sale	9.33	24,000	223,920		Jun 26 04:25 PM
Watton Corey Michael	Director	Mar 28 '25	Buy	7.84	300	2,352	1,800	Mar 31 08:05 PM
Bode John B	Director	Mar 19 '25	Buy	7.96	10,000	79,624	40,000	Mar 21 04:06 PM
Sangiovanni Timothy J.	SVP, Finance & Corp Controller	Feb 13 '25	Sale	7.86	3,000	23,588	16,341	Feb 14 05:57 PM
Schafer Joshua	CCO & EVP, Bus. Development	Feb 13 '25	Sale	7.86	10,500	82,527	29,486	Feb 14 05:55 PM
Clifton R. LaDuane	CFO & Treasurer	Feb 13 '25	Sale	7.86	11,000	86,471	51,361	Feb 14 05:55 PM
McFarlane Neil F.	President and CEO	Feb 13 '25	Sale	7.86	61,273	481,428	222,060	Feb 14 05:54 PM
McFarlane Neil F.	President and CEO	Feb 14 '25	Sale	8.05	30,544	245,962	191,516	Feb 14 05:54 PM
NEIL F MCFARLANE	Director	Feb 13 '25	Proposed Sale	7.72	91,817	708,827		Feb 13 04:38 PM
R. LADUANE CLIFTON	Officer	Feb 13 '25	Proposed Sale	7.72	11,000	84,920		Feb 13 04:29 PM
Timothy Sangiovanni	Officer	Feb 13 '25	Proposed Sale	7.72	3,000	23,160		Feb 13 04:29 PM
Joshua Schafer	Officer	Feb 13 '25	Proposed Sale	7.72	10,500	81,060		Feb 13 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVRA

Zevra Therapeutics Inc

Upgrade your FINVIZ experience